Table 1. Effect of vorinostat on protein expression of APM components in human breast carcinoma cells.
| % Positive (MFI) | ||||
|---|---|---|---|---|
| DMSO | Vorinostat | |||
| Antigen Processing Machinery | Intracellular | LMP2 | 86 (251) | 95 (363) |
| LMP7 | 19 (180) | 14 (190) | ||
| TAP1 | 43 (153) | 59 (171) | ||
| Tapasin | 64 (136) | 78 (160) | ||
| Calnexin | 85 (560) | 98 (857) | ||
| β2-microglobulin | 71 (115) | 96 (144) | ||
| Extracellular | HLA-ABC | 99 (195) | 100 (307) | |
| HLA-A2 | 99 (303) | 99 (304) | ||
| ICAM-1 | 77 (46) | 95 (131) | ||
| CEA | 14 (40) | 21 (23) | ||
| MUC1 | 9 (14) | 29 (24) | ||
MDA-MB-231 cells were exposed to vorinostat (3 μM) or vehicle (DMSO) control. At the end of treatment (96h), cells were analyzed by flow cytometry for cellular expression of indicated APM components. Bold denotes significant modulation (≥ 25% change in percent of cells or MFI not observed in isotype control vs. untreated cells).